At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 567 enrolled
Drug / intervention
Eslicarbazepine acetate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Therapy for Patients With Post-herpetic Neuralgia: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Eslicarbazepine acetate and Placebo for Postherpetic Neuralgia. Completed, enrolled 567 participants.
Detailed Summary
The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL) as therapy for patients with post-herpetic neuralgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
Primary CompletionJan 2009
First PostedSep 2009
TodayJul 2026
First PostedSep 22, 2009
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.8 years ago
Interventions
Eslicarbazepine acetatedrug
Scored tablets
Placebodrug
oral route